NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats - PubMed (original) (raw)
NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats
T Klockgether et al. Ann Neurol. 1990 Oct.
Abstract
Systemically administered N-methyl-D-aspartate (NMDA) antagonists, MK-801 ((+)5-methyl-10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5,10-imine maleate) and CPP (3-[(+-)-2-carboxypiperazin-4-yl]-propyl-1-phosphonate), potentiate the ability of L-dopa (L-3,4-dihydroxyphenylalanine) to reverse akinesia and to alleviate muscular rigidity in monoamine-depleted rats. On the basis of these findings, it is proposed that NMDA antagonists may be beneficial as adjunctive treatment in the therapy of Parkinson's disease. CPP locally injected into the subthalamic nucleus, entopeduncular nucleus--the rat homologue of the internal pallidal segment--or substantia nigra pars reticulata of monoamine-depleted rats stimulates locomotor activity and alleviates rigidity, whereas local microinjection of CPP into the neostriatum is ineffective. These results make it unlikely that the neostriatum is the site of the antiparkinsonian action of NMDA antagonists in monoamine-depleted rats, whereas the subthalamic nucleus, internal pallidal segment, and substantia nigra pars reticulata appear to be important for the effects of NMDA antagonists.
Similar articles
- Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease.
Greenamyre JT, Eller RV, Zhang Z, Ovadia A, Kurlan R, Gash DM. Greenamyre JT, et al. Ann Neurol. 1994 Jun;35(6):655-61. doi: 10.1002/ana.410350605. Ann Neurol. 1994. PMID: 8210221 - NMDA receptor antagonism potentiates the L-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats.
El Arfani A, Bentea E, Aourz N, Ampe B, De Deurwaerdère P, Van Eeckhaut A, Massie A, Sarre S, Smolders I, Michotte Y. El Arfani A, et al. Neuropharmacology. 2014 Oct;85:198-205. doi: 10.1016/j.neuropharm.2014.05.024. Epub 2014 May 24. Neuropharmacology. 2014. PMID: 24863042 - Differential effects of intrastriatal and intranigral injections of glutamate antagonists on motor behaviour in the reserpine-treated rat.
Kaur S, Starr MS. Kaur S, et al. Neuroscience. 1997 Jan;76(2):345-54. doi: 10.1016/s0306-4522(96)00407-1. Neuroscience. 1997. PMID: 9015320 - N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease.
Greenamyre JT, O'Brien CF. Greenamyre JT, et al. Arch Neurol. 1991 Sep;48(9):977-81. doi: 10.1001/archneur.1991.00530210109030. Arch Neurol. 1991. PMID: 1835370 Review. - The role of excitatory amino acids in experimental models of Parkinson's disease.
Ossowska K. Ossowska K. J Neural Transm Park Dis Dement Sect. 1994;8(1-2):39-71. doi: 10.1007/BF02250917. J Neural Transm Park Dis Dement Sect. 1994. PMID: 7534462 Review.
Cited by
- The substantia nigra conveys target-dependent excitatory and inhibitory outputs from the basal ganglia to the thalamus.
Antal M, Beneduce BM, Regehr WG. Antal M, et al. J Neurosci. 2014 Jun 4;34(23):8032-42. doi: 10.1523/JNEUROSCI.0236-14.2014. J Neurosci. 2014. PMID: 24899724 Free PMC article. - Alprazolam dependence prevented by substituting with the beta-carboline abecarnil.
Pinna G, Galici R, Schneider HH, Stephens DN, Turski L. Pinna G, et al. Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2719-23. doi: 10.1073/pnas.94.6.2719. Proc Natl Acad Sci U S A. 1997. PMID: 9122263 Free PMC article. - Metabotropic glutamate receptors for Parkinson's disease therapy.
Gasparini F, Di Paolo T, Gomez-Mancilla B. Gasparini F, et al. Parkinsons Dis. 2013;2013:196028. doi: 10.1155/2013/196028. Epub 2013 Jun 19. Parkinsons Dis. 2013. PMID: 23853735 Free PMC article. - Functional interaction between mGlu 5 and NMDA receptors in a rat model of Parkinson's disease.
Turle-Lorenzo N, Breysse N, Baunez C, Amalric M. Turle-Lorenzo N, et al. Psychopharmacology (Berl). 2005 Apr;179(1):117-27. doi: 10.1007/s00213-005-2202-x. Epub 2005 Feb 22. Psychopharmacology (Berl). 2005. PMID: 15726332 - The neuroprotectant properties of glutamate antagonists and antiglutamatergic drugs.
Pedersen V, Schmidt WJ. Pedersen V, et al. Neurotox Res. 2000;2(2-3):179-204. doi: 10.1007/BF03033793. Neurotox Res. 2000. PMID: 16787840
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous